LBD

LBD consolidates experimentally validated lymphoma biomarkers into a centralized resource to support diagnostic, prognostic, and treatment-related research.

Key Features:

• Extensive biomarker collection: Contains 793 biomarkers compiled from 978 PubMed articles, including 715 single biomarkers and 78 combined biomarkers.
• Biomarker categories: Categorizes biomarkers as molecular (DNA, RNA, proteins, chemical entities), cellular (cell types or counts), image (imaging technologies or parameters), histopathological, and physiological biomarkers.
• Functional classification: Annotates biomarkers according to roles in diagnosis, prognosis, and treatment.
• Manual curation and experimental validation: Entries are manually curated and supported by experimental evidence reported in the source literature.

Scientific Applications:

• Personalized diagnosis: Provides subtype-specific biomarker information to support more precise diagnostic interpretation.
• Prognostic evaluation: Enables identification of biomarkers associated with patient outcomes for prognostic assessments.
• Therapeutic development: Supplies treatment-related biomarker data to support development and optimization of targeted therapies.

Methodology:

Systematic extraction and validation from peer-reviewed scientific literature, with inclusion only of biomarkers supported by experimental evidence.